Ipilimumab in the Adjuvant Setting for Melanoma

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.

Clinical Pearls

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.

  • There are a number of studies looking at ipilimumab in the adjuvant setting
  • There has been a fair amount of toxicity associated with the 10-mg/kg dosage
  • Adjuvant therapy with ipilimumab outside of a clinical trial is not recommended